Are we still in a golden age for biotech investing? Join the discussion at noon.


Nathan Vardi

Managing Editor for Enterpris, MarketWatch

Nathan Vardi is MarketWatch’s managing editor for enterprise, driving features, long-form and investigative journalism across the business news site. Previously, Nathan was a senior editor at Forbes. He is currently writing “For Blood and Money,” a book about cancer drug development, to be published by W.W. Norton & Co.

This article was originally published by Read the original article here.

Previous article: Tesla’s Texas factory extension likely a topic at EV maker’s investor day
Next articleThe Ratings Game: Salesforce stock hit by downgrade as cloud-software giant falls into ‘growth purgatory’


Please enter your comment!
Please enter your name here